secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATAI Life Sciences N.V. (—)
CIK:        0001840904
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001140361-25-040429
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atai Beckley completes acquisition of Beckley Psytech, creating AtaiBeckley; issues ~105M shares
--------------------------------------------------------------------------------

- Consideration of ~105M new shares issued to Beckley Psytech shareholders, representing ~28% of combined company.
- Combined cash expected to fund operations into 2029, through first Phase 3 trial of BPL-003 for TRD.
- BPL-003 (mebufotenin benzoate nasal spray) is Phase 3-ready; End-of-Phase 2 FDA meeting scheduled, Phase 3 start Q2 2026.
- Board: Christian Angermayer (Chairman), Scott Braunstein (Vice Chairman), Cosmo Feilding Mellen, Robert Hershberg.
- Shareholders approved redomiciliation to Delaware; expected completion around year-end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/0001140361-25-040429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/ef20058318_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-040429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer